<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Breast Cancer Res</journal-id><journal-title>Breast Cancer Research</journal-title><issn pub-type="ppub">1465-5411</issn><issn pub-type="epub">1465-542X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">16280043</article-id><article-id pub-id-type="pmc">1410755</article-id><article-id pub-id-type="publisher-id">bcr1326</article-id><article-id pub-id-type="doi">10.1186/bcr1326</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter</subject></subj-group></article-categories><title-group><article-title>CYP2D6 variants and the prediction of tamoxifen response in randomized patients: author response</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Wegman</surname><given-names>Pia P</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>piapa@ibk.liu.se</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Wingren</surname><given-names>Sten</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>Department of Biomedicine and Surgery, Division of Cell Biology, Faculty of Health Sciences, Linköping, Sweden</aff><pub-date pub-type="ppub"><year>2005</year></pub-date><pub-date pub-type="epub"><day>29</day><month>9</month><year>2005</year></pub-date><volume>7</volume><issue>6</issue><fpage>E7</fpage><lpage>E7</lpage><ext-link ext-link-type="uri" xlink:href="http://breast-cancer-research.com/content/7/6/E7"></ext-link><copyright-statement>Copyright © 2005 BioMed Central Ltd</copyright-statement></article-meta><notes><p>See related research by Wegman et al. in issue 7.3 <ext-link ext-link-type="uri" xlink:href="http://breast-cancer-research.com/content/7/3/R284"></ext-link> and letter by Rae et al. online <ext-link ext-link-type="uri" xlink:href="http://breast-cancer-research.com/content/7/5/E6"></ext-link>.</p></notes></front><body><sec><title></title><p><offsets xml_i="2215" xml_f="2234" txt_i="8" txt_f="27">Rae and coworkers [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="2265" xml_f="2266" txt_i="27" txt_f="28">1</offsets></xref><offsets xml_i="2273" xml_f="2348" txt_i="28" txt_f="103">] argued that there may be selection bias in our recently published study [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="2379" xml_f="2380" txt_i="103" txt_f="104">2</offsets></xref><offsets xml_i="2387" xml_f="2472" txt_i="104" txt_f="189">] and that, in fact, our findings are consistent with their previously reported data.</offsets></p><p><offsets xml_i="2479" xml_f="2537" txt_i="190" txt_f="248">Our study (hereafter referred to as the 'current study') [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="2568" xml_f="2569" txt_i="248" txt_f="249">2</offsets></xref><offsets xml_i="2576" xml_f="3486" txt_i="249" txt_f="1159">] was conducted to validate whether polymorphisms in genes that encode metabolic enzymes may predict the response to tamoxifen among oestrogen receptor (ER)-positive postmenopausal breast cancer patients randomly assigned to treatment with or without tamoxifen. The initial trial was begun in 1976 in Stockholm, Sweden and patient material from approximately one-third of the initial population was available for use in the current study. In the Materials and method section of the report we compared characteristics such as lymph node status, ER status and tumour size between the initial and current study populations, and found that these parameters were similarly distributed throughout the populations. However, despite these similarities, selection bias could not be completely excluded, and this was noted in our conclusion, as was the need for confirmation of our findings in a larger randomized trial.</offsets></p><p><offsets xml_i="3493" xml_f="3578" txt_i="1160" txt_f="1245">Initially, we assessed possible differences in prognostic value between genotypes of </offsets><italic><offsets xml_i="3586" xml_f="3593" txt_i="1245" txt_f="1252">CYP2D6 </offsets></italic><offsets xml_i="3602" xml_f="3606" txt_i="1252" txt_f="1256">and </offsets><italic><offsets xml_i="3614" xml_f="3622" txt_i="1256" txt_f="1264">SULT1A1 </offsets></italic><offsets xml_i="3631" xml_f="3883" txt_i="1264" txt_f="1516">in the study population (including both ER-negative and ER-positive patients). However, the primary aim was to investigate whether these genotypes could predict response to tamoxifen therapy in ER-positive patients. Strikingly, patients with different </offsets><italic><offsets xml_i="3891" xml_f="3898" txt_i="1516" txt_f="1523">CYP2D6 </offsets></italic><offsets xml_i="3907" xml_f="4042" txt_i="1523" txt_f="1658">genotypes responded differently to therapy. We found no variation in distant recurrence-free survival among homozygous carriers of the </offsets><italic><offsets xml_i="4050" xml_f="4059" txt_i="1658" txt_f="1667">CYP2D6*1 </offsets></italic><offsets xml_i="4068" xml_f="4134" txt_i="1667" txt_f="1733">allele, but a significant difference was noted in carriers of the </offsets><italic><offsets xml_i="4142" xml_f="4151" txt_i="1733" txt_f="1742">CYP2D6*4 </offsets></italic><offsets xml_i="4160" xml_f="4200" txt_i="1742" txt_f="1782">allele. Recently, Nowell and coworkers [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="4231" xml_f="4232" txt_i="1782" txt_f="1783">3</offsets></xref><offsets xml_i="4239" xml_f="4303" txt_i="1783" txt_f="1847">] conducted a similar study in which they investigated the same </offsets><italic><offsets xml_i="4311" xml_f="4318" txt_i="1847" txt_f="1854">CYP2D6 </offsets></italic><offsets xml_i="4327" xml_f="4427" txt_i="1854" txt_f="1954">polymorphism in patients either receiving or not receiving tamoxifen treatment. They found that the </offsets><italic><offsets xml_i="4435" xml_f="4444" txt_i="1954" txt_f="1963">CYP2D6*4 </offsets></italic><offsets xml_i="4453" xml_f="4635" txt_i="1963" txt_f="2145">variant allele appeared to be associated with decreases in death and recurrence rates. To our knowledge, no previous studies have been performed to elucidate the predictive value of </offsets><italic><offsets xml_i="4643" xml_f="4650" txt_i="2145" txt_f="2152">CYP2D6 </offsets></italic><offsets xml_i="4659" xml_f="4692" txt_i="2152" txt_f="2185">genotypes on tamoxifen treatment.</offsets></p><p><offsets xml_i="4699" xml_f="4719" txt_i="2186" txt_f="2206">Rae and colleagues [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="4750" xml_f="4751" txt_i="2206" txt_f="2207">1</offsets></xref><offsets xml_i="4758" xml_f="4830" txt_i="2207" txt_f="2279">] interpret our data as consistent with their findings, suggesting that </offsets><italic><offsets xml_i="4838" xml_f="4845" txt_i="2279" txt_f="2286">CYP2D6 </offsets></italic><offsets xml_i="4854" xml_f="5147" txt_i="2286" txt_f="2579">poor metabolizers may derive less benefit from tamoxifen treatment. We disagree with that view. In support of their conclusion, Dr Rae and colleagues cite a meeting abstract of a study in which all patients were treated with tamoxifen and were not randomized according to tamoxifen treatment [</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="5178" xml_f="5179" txt_i="2579" txt_f="2580">4</offsets></xref><offsets xml_i="5186" xml_f="5519" txt_i="2580" txt_f="2913">]. Our analysis represents a different comparison than that reported by Goetz and coworkers because, even though the sample population sizes are similar, result interpretation is highly dependent on randomization and study design. In our opinion we cannot endorse Dr. Rae's statement that our findings are consistent with their data.</offsets></p></sec><sec><title><offsets xml_i="5541" xml_f="5560" txt_i="2915" txt_f="2934">Competing interests</offsets></title><p><offsets xml_i="5571" xml_f="5631" txt_i="2935" txt_f="2995">The author(s) declare that they have no competing interests.</offsets></p></sec></body><back><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rae</surname><given-names>JM</given-names></name><name><surname>Goetz</surname><given-names>MP</given-names></name><name><surname>Hayes</surname><given-names>DF</given-names></name><name><surname>Ingle</surname><given-names>JN</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Storniolo</surname><given-names>AM</given-names></name><name><surname>Stearns</surname><given-names>V</given-names></name><name><surname>Flockhart</surname><given-names>DA</given-names></name></person-group><article-title>CYP2D6 genotype and tamoxifen response</article-title><source>Breast Cancer Res</source><year>2005</year><volume>7</volume><fpage>E6</fpage><pub-id pub-id-type="pmid">16168100</pub-id><pub-id pub-id-type="doi">10.1186/bcr1297</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wegman</surname><given-names>P</given-names></name><name><surname>Vainikka</surname><given-names>L</given-names></name><name><surname>Stål</surname><given-names>O</given-names></name><name><surname>Nordenskjöld</surname><given-names>B</given-names></name><name><surname>Skoog</surname><given-names>L</given-names></name><name><surname>Rutqvist</surname><given-names>L-E</given-names></name><name><surname>Wingren</surname><given-names>S</given-names></name></person-group><article-title>Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients</article-title><source>Breast Cancer Res</source><year>2005</year><volume>7</volume><fpage>R284</fpage><lpage>R290</lpage><pub-id pub-id-type="pmid">15987423</pub-id><pub-id pub-id-type="doi">10.1186/bcr993</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nowell</surname><given-names>SA</given-names></name><name><surname>Ahn</surname><given-names>J</given-names></name><name><surname>Rae</surname><given-names>JM</given-names></name><name><surname>Scheys</surname><given-names>JO</given-names></name><name><surname>Trovato</surname><given-names>A</given-names></name><name><surname>Sweeney</surname><given-names>C</given-names></name><name><surname>MacLeod</surname><given-names>SL</given-names></name><name><surname>Kadlubar</surname><given-names>FF</given-names></name><name><surname>Ambrosone</surname><given-names>CB</given-names></name></person-group><article-title>Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients</article-title><source>Breast Cancer Res Treat</source><year>2005</year><volume>91</volume><fpage>249</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">15952058</pub-id><pub-id pub-id-type="doi">10.1007/s10549-004-7751-x</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goetz</surname><given-names>MP</given-names></name><name><surname>Rae</surname><given-names>JM</given-names></name><name><surname>Suman</surname><given-names>VJ</given-names></name><name><surname>Safgren</surname><given-names>SL</given-names></name><name><surname>Ames</surname><given-names>MM</given-names></name><name><surname>Vissche</surname><given-names>DW</given-names></name><name><surname>Flockhart</surname><given-names>DA</given-names></name><name><surname>Adjei</surname><given-names>AA</given-names></name><name><surname>Weinshilboum</surname><given-names>RM</given-names></name><name><surname>Couch</surname><given-names>FJ</given-names></name><etal></etal></person-group><article-title>Pharmacogenomic determinants of outcome with tamoxifen therapy: findings from the randomized North Central Cancer Treatment Group adjuvant breast cancer trial 89-30-52</article-title><source>Breast Cancer Res Treat</source><year>2004</year><volume>88</volume><fpage>S35</fpage></citation></ref></ref-list></back></article>